Bonum is a biotechnology company developing protein-based therapeutics that are activated only where needed.  Its proprietary Dual-Binding Antibody platform uses a novel mechanism to retain protein therapeutics in an inactive state in circulation but to activate in the presence of a marker – enabling precise control over therapeutic activity for reduced systemic toxicity and increase efficacy.